In the field of drug discovery, targeting DNA Damage Response (DDR) pathways and exploiting synthetic lethality have emerged as powerful strategies for developing novel cancer therapies. The DDR system is crucial for maintaining genomic integrity by detecting and repairing DNA damage. When DDR pathways are compromised, cells become reliant on alternative repair mechanisms. This vulnerability can be therapeutically targeted using synthetic lethality, where the simultaneous inhibition of two genes leads to cell death, while inhibition of either gene alone is non-lethal.
Our services at ICE Bioscience are designed to support DDR and synthetic lethality drug research, offering comprehensive solutions from protein expression to in vivo models. By leveraging our advanced assays and extensive expertise, we enable the identification and validation of novel therapeutic targets, driving forward the development of effective cancer treatments.
✅ Extensive Protein Products: Over 60 validated recombinant proteins related to DDR and Synthetic Lethality.
✅ Advanced Biochemical and Biophysical Platforms: Utilizing more than 10 assay formats, including ADP-Glo, HTRF, FP, and SPR, we offer hundreds of ready-to-use DDR-targeting assays. Our services cover popular targets such as WRN, PARP, CDK, POLQ, PARG, PKMYT1, PRMT5 and p53.
✅ Specialized Cell Lines and Cell-based Assays: A diverse collection of cell lines, including KO and drug-resistant variants, supporting viability, biomarker, and reporter assays.
✅ Custom In Vivo Models: Tailored in vivo models specifically developed for DDR research.
To learn more about our comprehensive DDR service capabilities, please download our brochure.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
